List of Excipients in Branded Drug GOOD SENSE ANTIDIARRHEAL

Generic Drugs Containing GOOD SENSE ANTIDIARRHEAL

Company	Ingredient	NDC	Excipient
L Perrigo Company	loperamide hcl	0113-1645	ANHYDROUS CITRIC ACID
L Perrigo Company	loperamide hcl	0113-1645	CARBOXYMETHYLCELLULOSE SODIUM
L Perrigo Company	loperamide hcl	0113-1645	CELLULOSE, MICROCRYSTALLINE

What are the Most Frequently-Used Excipients in GOOD SENSE ANTIDIARRHEAL?

# Of NDCs	Excipient
2	ANHYDROUS CITRIC ACID
2	CARBOXYMETHYLCELLULOSE SODIUM
2	CELLULOSE, MICROCRYSTALLINE

Good Sense Antidiarrheal Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

Good Sense Antidiarrheal is an over-the-counter loperamide hydrochloride product used for short-term control of diarrhea. Its commercial opportunity is driven less by active-ingredient exclusivity and more by low-cost manufacturing, dosage-form differentiation, retailer access, packaging compliance, and consumer usability. Loperamide is an established OTC monograph ingredient, so excipient choices should prioritize robust manufacturability, rapid release, stability, taste control, and low unit cost rather than patent exclusivity.

What drug is in Good Sense Antidiarrheal?

Good Sense Antidiarrheal contains loperamide hydrochloride, generally at a 2 mg strength per dosage unit for the caplet format. Loperamide is an opioid-receptor agonist that acts primarily in the gastrointestinal tract and is marketed for symptomatic relief of acute diarrhea.

The product is sold under the GoodSense private-label OTC portfolio. Retailer-specific packaging and the responsible manufacturer or distributor can vary by stock-keeping unit and market channel. The applicable Drug Facts labeling generally limits use to adults and children aged 6 years and older, with dosing restrictions and warnings relating to prolonged symptoms, fever, bloody stool, mucus, and abdominal swelling.

Attribute	Good Sense Antidiarrheal
Active ingredient	Loperamide hydrochloride
Typical strength	2 mg per caplet or dosage unit
Regulatory category	OTC human drug
Primary indication	Relief of diarrhea symptoms
Likely dosage forms	Caplets, tablets, or liquid depending on SKU
Core commercial channel	Retail pharmacy, mass merchandise, grocery, e-commerce
Principal competitive set	Imodium A-D, store-brand loperamide, generic loperamide products
Primary value driver	Low-cost, compliant symptom relief

The product’s regulatory positioning is principally governed by the FDA OTC monograph framework for antidiarrheal products, including loperamide requirements under 21 C.F.R. Part 335 and applicable labeling provisions under 21 C.F.R. Part 201.[1][2]

What excipients are used in Good Sense Antidiarrheal?

Public labels for loperamide caplets commonly identify conventional tablet excipients, including microcrystalline cellulose, dibasic calcium phosphate, pregelatinized starch, crospovidone, colloidal silicon dioxide, and magnesium stearate. Film-coated products can also contain coating polymers, plasticizers, opacifiers, and colorants. Exact inactive ingredients should be confirmed against the current package label for the specific NDC and dosage form.

Excipient class	Typical examples	Functional role
Diluent	Microcrystalline cellulose, dibasic calcium phosphate	Provides tablet mass and compressibility
Binder	Pregelatinized starch, copovidone or related polymer	Improves granule and tablet cohesion
Disintegrant	Crospovidone, sodium starch glycolate	Promotes tablet breakup after ingestion
Glidant	Colloidal silicon dioxide	Improves powder flow
Lubricant	Magnesium stearate	Reduces tooling friction and ejection force
Film coating	Hypromellose, polyethylene glycol, mineral opacifier	Improves swallowability, appearance, and handling
Colorant	Approved synthetic or mineral colorant	Supports product identification and branding

The excipient system is commercially important because loperamide is administered at a low dose relative to the tablet mass. The formulation must distribute a small quantity of active ingredient uniformly through a larger powder blend. Blend uniformity, segregation control, tablet hardness, friability, disintegration, and dissolution are the principal technical risks.

How should the excipient strategy be optimized?

A cost-effective strategy should use a direct-compression platform where the selected loperamide hydrochloride grade has adequate flow, particle-size control, and content uniformity. Direct compression can reduce processing steps, solvent use, drying time, and manufacturing cost.

A conventional platform would use:

1. Microcrystalline cellulose or a comparable compressible filler.
2. Pregelatinized starch or a dry binder to improve mechanical strength.
3. Crospovidone for rapid disintegration.
4. Colloidal silicon dioxide for flow improvement.
5. Magnesium stearate at the minimum validated concentration needed for lubrication.
6. A thin film coat where swallowability, color coding, and tablet protection justify the added cost.

Why direct compression is commercially attractive

Loperamide products compete primarily on retail price and availability. Direct compression supports:

• Lower conversion cost.
• Fewer unit operations.
• Reduced equipment requirements.
• Shorter batch cycle times.
• Easier scale-up across contract manufacturing sites.
• Simplified line extensions using the same excipient platform.

A wet-granulation process may be justified if the selected loperamide API has poor flow, excessive segregation, or unacceptable content-uniformity performance. It is less attractive when the product can meet specifications through controlled particle engineering and dry blending.

How can content uniformity be protected?

Low-dose drug products require tighter control of API particle size, bulk density, electrostatic behavior, and mixing order. The formulation should be evaluated for:

• API-to-excipient particle-size mismatch.
• Segregation during transfer and hopper discharge.
• Blend sampling bias.
• Lubrication sensitivity.
• Compression-force effects on dissolution.
• Over-lubrication caused by excessive magnesium stearate blending.

A preblend or ordered-addition process can improve distribution of loperamide hydrochloride. The commercial objective is not simply a low-cost tablet. It is a tablet that maintains uniformity across high-speed compression, packaging, transportation, and shelf life.

What formulation opportunities exist for Good Sense Antidiarrheal?

The strongest opportunities are dosage-form and usability improvements rather than new chemical entities. Loperamide’s established status limits the value of conventional composition claims, but formulation execution can create operational and consumer advantages.

Fast-disintegrating caplets

A rapidly disintegrating caplet can improve perceived onset and swallowing convenience. Crospovidone, porous filler systems, reduced coating weight, and controlled compression force can support faster tablet breakup without requiring a new active ingredient.

The product must still meet dissolution and stability specifications. Very aggressive disintegration can create friability, dusting, capping, and packaging losses.

Chewable tablets

Chewable loperamide products could target consumers who have difficulty swallowing conventional caplets. The primary excipient issues are:

• Bitter taste masking.
• Mouthfeel.
• Tablet hardness.
• Abrasion resistance.
• Sweetener and flavor stability.
• Moisture protection.

Ion-exchange resins, polymeric taste-masking systems, coated API particles, or lipid-based barriers could be evaluated. The commercial benefit must offset higher formulation cost and more complex process validation.

Orally disintegrating tablets

An orally disintegrating tablet could provide a differentiated product for travel, emergency use, and consumers without immediate access to water. The formulation would require low-moisture excipients, strong packaging protection, and acceptable taste.

Potential excipient systems include mannitol, microcrystalline cellulose, crospovidone, low-substituted hydroxypropyl cellulose, and flavor or sweetener combinations. The principal risks are hygroscopicity, tablet friability, and unpleasant taste from rapid API exposure.

Liquid formulations

A liquid loperamide product could address pediatric or swallowing-related use cases. The formulation would require a carefully controlled preservative system, viscosity modifier, flavoring system, and dose-measuring device.

Liquid products carry higher microbial, stability, packaging, and dosing risks than caplets. They also require strict age-related labeling controls. The commercial case is stronger when the product targets a specific underserved user group rather than competing directly with low-cost tablets.

Unit-dose travel packaging

Blister packaging and small travel packs are commercially attractive because diarrhea treatment is often purchased for travel, emergency kits, and workplace first-aid supplies. Packaging is not an excipient strategy, but it can increase product differentiation without changing the formulation.

A unit-dose format can improve portability and dose tracking. It also increases packaging cost and may reduce the number of units per retail shelf footprint.

What FDA regulatory status applies to Good Sense Antidiarrheal?

Loperamide hydrochloride is an established OTC antidiarrheal ingredient. OTC products must comply with the applicable monograph conditions, labeling requirements, current good manufacturing practice rules, packaging standards, and postmarket reporting obligations.

The FDA’s OTC monograph system permits compliant products to be marketed without an individual new drug application when the product satisfies the applicable monograph conditions. The FDA’s final administrative order framework under the CARES Act has replaced the former monograph rulemaking structure for many OTC categories, but the governing ingredient, dosage, labeling, and manufacturing requirements remain central to commercialization.[3]

For Good Sense Antidiarrheal, regulatory diligence should focus on:

• The exact NDC and product label.
• Active and inactive ingredient declarations.
• Dosage form and strength.
• Drug Facts compliance.
• Child-resistant packaging requirements where applicable.
• Tamper-evident packaging.
• Stability data.
• Manufacturing-site compliance.
• Labeling restrictions related to children and maximum daily dose.

What is the Orange Book status of Good Sense Antidiarrheal?

The Orange Book is primarily relevant to approved prescription and certain approved OTC drug products. A conventional OTC monograph loperamide product generally does not depend on an Orange Book patent listing for market access.

The commercial protection model is therefore different from that of a branded prescription drug. Key barriers are regulatory compliance, manufacturing capability, retailer qualification, supply reliability, packaging execution, and brand positioning. A competitor generally does not need to wait for a branded patent expiration if it can lawfully market a compliant loperamide product under the OTC framework.

When does Good Sense Antidiarrheal lose exclusivity?

Good Sense Antidiarrheal does not have the exclusivity profile of a patented prescription product. Loperamide has been marketed for decades, and multiple generic and private-label competitors are available. The product’s commercial exclusivity is based mainly on retailer distribution, brand recognition, price, packaging, and supply agreements.

Exclusivity type	Relevance to Good Sense Antidiarrheal
Active-ingredient patent	No meaningful current barrier for conventional loperamide
New chemical entity exclusivity	Not applicable
Prescription generic exclusivity	Not applicable to a standard OTC monograph product
OTC monograph access	Available to compliant competitors
Trademark protection	Applies to the GoodSense brand, not loperamide
Private-label agreement	May restrict commercial access to a retailer channel
Formulation protection	Possible only for genuinely differentiated and patentable technology
Manufacturing know-how	Potentially valuable but generally difficult to enforce alone

A new formulation with a novel taste-masking system, controlled-release profile, packaging-device combination, or technically distinct manufacturing process could create patent or trade-secret value. The patent position would depend on claim scope, prior art, enablement, and the degree of technical differentiation.

How strong is the patent estate for loperamide products?

The patent estate for conventional immediate-release loperamide tablets is weak as a market barrier because the active ingredient, indication, and basic dosage form are mature. A new entrant can generally compete through established OTC pathways and standard excipient systems.

Patent value may be stronger in the following areas:

• Taste-masked loperamide particles.
• Orally disintegrating dosage forms.
• Controlled-release delivery.
• Combination products with a distinct therapeutic rationale.
• Abuse-deterrent or misuse-resistant presentations.
• Novel packaging and dosing systems.
• Manufacturing processes that materially improve uniformity or stability.

A formulation patent must provide more than a routine substitution of one standard filler or disintegrant for another. The strongest claims would link the excipient architecture to a measurable technical effect, such as improved dissolution, reduced bitterness, enhanced stability, reduced segregation, or improved manufacturability.

Which companies are challenging Good Sense Antidiarrheal?

Competition comes from private-label retailers, generic-drug manufacturers, and branded loperamide suppliers. Imodium A-D is the principal branded reference competitor. Store brands from pharmacy, grocery, club, and mass-retail chains compete on price and package count.

The competitive set includes:

• Branded loperamide products.
• Retailer-owned store brands.
• Generic loperamide manufacturers.
• E-commerce private-label sellers.
• Combination antidiarrheal products.
• Travel-health and first-aid brands.

The relevant challenge is usually not a Paragraph IV patent challenge. It is shelf-space competition, price compression, retailer substitution, and private-label sourcing. A supplier that can offer equivalent quality at lower conversion cost may win business even without a differentiated formulation.

What generic launch risks exist for Good Sense Antidiarrheal?

Generic launch risk is high for a standard loperamide caplet because technical and regulatory barriers are modest. The major risks are commercial rather than patent-related.

High-probability launch scenario

A competing manufacturer launches a conventional 2 mg loperamide caplet using a standard direct-compression formulation. It competes through lower cost, broader distribution, or a retailer supply agreement.

Moderate-opportunity scenario

A competitor introduces a chewable, fast-disintegrating, or travel-oriented format. The product uses taste masking, unit-dose packaging, or a differentiated tablet presentation to support a higher retail price.

Lower-probability scenario

A competitor develops a protected delivery platform with defensible claims and a meaningful patient or consumer benefit. This would require stronger clinical, usability, stability, or manufacturing evidence than a standard caplet.

How can excipient suppliers capture commercial value?

Excipient suppliers can pursue this market through performance-based formulation support rather than commodity volume alone. Attractive offerings include:

• Direct-compression excipient platforms for low-dose APIs.
• Co-processed fillers and disintegrants.
• Low-moisture systems for orally disintegrating tablets.
• Taste-masking polymers and coated API technologies.
• Excipient systems compatible with high-speed compression.
• Documentation packages supporting OTC quality and supplier qualification.
• Global regulatory support for multi-market private-label products.

The strongest commercial proposition is a validated platform that reduces development time and manufacturing failures across multiple loperamide SKUs. A supplier that improves flow, content uniformity, dissolution, and tablet robustness can compete on total cost rather than excipient price per kilogram.

What geographic opportunities exist?

The U.S. market is attractive because of established OTC demand, broad retail distribution, and strong private-label penetration. International opportunities depend on local classification, labeling, dosage limits, approved excipients, and prescription-versus-OTC status.

Potential expansion areas include:

• Canada and other markets with established loperamide OTC use.
• European markets where national or regional labeling rules apply.
• Travel-health channels.
• E-commerce markets with multi-pack and emergency-kit demand.
• Emerging markets where low-cost oral solid dosage manufacturing is scalable.

Geographic expansion increases the importance of excipient regulatory status. An ingredient accepted in the United States may require separate justification or may face different labeling and quality expectations elsewhere.

What licensing deals could create value?

Licensing opportunities are more likely to involve formulation technology, packaging, or manufacturing platforms than the loperamide molecule itself.

Potential deal structures include:

Deal type	Commercial rationale
Taste-masking license	Enables chewable or orally disintegrating products
Co-processed excipient supply agreement	Reduces scale-up and batch-variability risk
Private-label manufacturing agreement	Secures retailer volume
Packaging-device license	Supports travel packs or dose-tracking formats
Regional commercialization license	Expands distribution outside the supplier’s core market
Formulation know-how transfer	Accelerates launch of differentiated dosage forms

A formulation license is most defensible when it includes process parameters, analytical methods, stability data, and validated scale-up experience. A simple list of excipients has limited licensing value.

Key Takeaways

• Good Sense Antidiarrheal is a loperamide hydrochloride OTC product, typically supplied at 2 mg per dosage unit.
• Conventional loperamide caplets have limited patent-based exclusivity and face substantial generic and private-label competition.
• The most practical excipient platform is a direct-compression system built around a compressible filler, dry binder, superdisintegrant, glidant, and lubricant.
• Technical priorities are content uniformity, rapid disintegration, dissolution, tablet robustness, and low manufacturing cost.
• The strongest product opportunities are chewable, orally disintegrating, liquid, and unit-dose travel formats.
• Taste masking and moisture protection are the central formulation challenges for differentiated dosage forms.
• Commercial value is concentrated in retailer access, private-label supply, manufacturing efficiency, packaging, and formulation know-how.
• Standard OTC monograph access makes conventional generic launch risk high.
• Patent value is more plausible for technically differentiated delivery systems than for routine excipient substitutions.
• Excipient suppliers can create leverage through validated, multi-SKU formulation platforms and technical services.

FAQs

Is Good Sense Antidiarrheal the same as Imodium A-D?

Both products generally use loperamide hydrochloride as the active ingredient. They can differ in inactive ingredients, dosage form, tablet appearance, package size, labeling presentation, manufacturer, and price.

Can loperamide be reformulated with different excipients?

Yes. A manufacturer can use different inactive ingredients if the formulation remains compliant with applicable FDA requirements and the product meets identity, strength, quality, purity, stability, dissolution, and labeling standards.

Is loperamide suitable for an orally disintegrating tablet?

Loperamide can be evaluated for an orally disintegrating tablet, but taste masking, low-dose content uniformity, friability, moisture sensitivity, and packaging protection are major development issues.

Does a new loperamide excipient combination automatically receive patent protection?

No. A patentable formulation generally requires novelty, non-obviousness, adequate disclosure, and a credible technical benefit. Routine substitution of common tablet excipients is unlikely to create strong protection.

What is the best commercial opportunity in loperamide formulation?

For a private-label product, the best near-term opportunity is usually a low-cost, robust immediate-release caplet or a travel-oriented unit-dose pack. For a premium product, chewable or orally disintegrating loperamide with effective taste masking offers greater differentiation.

References

1. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 335: Antidiarrheal products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-335

2. U.S. Food and Drug Administration. (2024). Code of Federal Regulations, Title 21, Part 201: Labeling. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201

3. U.S. Food and Drug Administration. (2024). Over-the-counter monograph drugs. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monograph-reform

4. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/